Antibody therapies that rely on FcγR engagement are used to treat cancer, autoimmune, and neurodegenerative diseases (Chao et al., 2010; Nimmerjahn and Ravetch, 2005; Uchida et al., 2004; Watanabe et al., 1999; Weiskopf et al., 2013; Weiskopf and Weissman, 2015). This evidence concerns the gene FCGR2A and neurodegenerative disease.